Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04521582
Other study ID # RB00011513
Secondary ID 744 - 2019
Status Completed
Phase N/A
First received
Last updated
Start date April 27, 2021
Est. completion date July 20, 2022

Study information

Verified date July 2022
Source Johns Hopkins Bloomberg School of Public Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators will evaluate whether a system involving Female Community Health Volunteers (FCHVs) and facility-based community health workers (FB-CHWs) of Health Post (Auxiliary Health Workers, Auxiliary Nurse Midwives and Health Assistant) can contribute to improving hypertension care in rural Nepal. This study will be conducted in Rupa (active group) and Biruwa (comparison group) Rural Municipality of Gandaki province and enroll at least 736 hypertensive adults (322 in Rupa Rural Municipality and 414 in Biruwa Rural Municipality) who are aged 25-70 years, not taking antihypertensive medication, not pregnant and not breastfeeding, free of prior cardiovascular disease, chronic kidney disease, and diabetes. In Rupa Municipality, eligible participants will be able to receive amlodipine, one of the most frequently used antihypertensive medications, from FB-CHWs at Health Posts and five times (including baseline and end of study) of lifestyle counseling by FCHVs, whereas participants in Biruwa Municipality will receive the usual care plus three times (including baseline and end of study) of lifestyle counseling by FCHVs.


Description:

Despite a large body of evidence on the effectiveness of hypertension treatment in reducing cardiovascular morbidity and mortality, the control rate of hypertension is low in many low and middle-income countries. The shortage of skilled workforce diagnosing and managing hypertension is one of the major barriers. A promising option is to involve community health workers (CHWs) in hypertension care, who have shown promising results for improving maternal and child health. However, the evidence on whether CHWs can diagnose and treat hypertension under the supervision of a physician has not been systematically tested. Thus, this study will evaluate whether existing Facility Based-Community Health Workers (FB-CHWs) and Female Community Health Volunteers (FCHVs) of the Ministry of Health can safely and effectively diagnose hypertension and initiate/maintain protocol-based hypertension treatment. This study will be conducted in Rupa (active group) and the Biruwa (comparison group) Rural Municipality of Gandaki province. All adults aged 25-70 years of age who reside in the Rupa and Biruwa municipalities are eligible for the initial screening by data enumerators of the Nepal Development Society (NeDS). Only eligible participants who meet the inclusion criteria will participate in the study. Rupa Rural Municipality will allow the initiation of antihypertensive medication (amlodipine) by FB-CHW at Health Posts under the supervision of a study physician. Biruwa Rural Municipality will follow usual care, which is a referral to healthcare facilities currently providing hypertension care. FCHVs will provide lifestyle counseling and follow up the adherence to hypertension treatment three times in Rupa Rural Municipality and once in Biruwa Rural Municipality.FCHV in Rupa Rural Municipality will make three home visits (at 3, 6, and 9 months) whereas FCHV in Biruwa Rural Municipality will make one home visit after 3 months of baseline. The end of the study survey will be carried out after one year by FCHV and NeDS data enumerators. The primary study outcome is a net change in systolic blood pressure among hypertensive participants 12-months after confirming hypertension in the active vs. the comparison group.


Recruitment information / eligibility

Status Completed
Enrollment 1428
Est. completion date July 20, 2022
Est. primary completion date April 20, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years to 70 Years
Eligibility Inclusion criteria - Between 25-70 years old - Systolic blood pressure 140-179 mmHg or diastolic blood pressure 90-119 mmHg - Do not have a plan to leave the study municipality within a year Exclusion criteria - Use of antihypertensive medication in the last two weeks - History of stroke, heart attack, heart failure, or chronic kidney disease - History of diabetes meritus - Pregnant or any plan to be pregnant in a year - Breastfeeding

Study Design


Intervention

Drug:
Amlodipine
The facility-based community health worker will receive protocol-driven training to initiate amlodipine for hypertensive patients. These patients will receive lifestyle counseling by Female Community Health Volunteer through home visits (5 times [including baseline and end of the study] in the active municipality and 3 times [including baseline and end of the study] in the control municipality).
Behavioral:
Lifestyle counselling
Female Community Health Volunteer will provide lifestyle counseling at the participant's home

Locations

Country Name City State
Nepal Rupa Rural Municipality Kaski Gandaki
Nepal Biruwa Rural Municipality Syangja Gandaki

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins Bloomberg School of Public Health Nepal Development Society

Country where clinical trial is conducted

Nepal, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean change in systolic blood pressure To assess the longitudinal association of the intervention with changes in blood pressure over time, linear mixed effect models with a three-level hierarchical approach will be used. One year
Primary Mean change in diastolic blood pressure To assess the longitudinal association of the intervention with changes in blood pressure over time, linear mixed effect models with a three-level hierarchical approach will be used. One year
Secondary Percentage of hypertension control (<140/90) among study participants Systolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg One year
See also
  Status Clinical Trial Phase
Completed NCT05086549 - An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
Recruiting NCT05086523 - Cardiac Neuromodulation Therapy (CNT) "Washout" Sub-Study Phase 1/Phase 2
Active, not recruiting NCT03503773 - The TARGET BP OFF-MED Trial Phase 2
Not yet recruiting NCT04082091 - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Recruiting NCT06019598 - Licorice and Home Blood Pressure, Additional Study N/A
Completed NCT04495231 - Sympathetic Activity and Cardiometabolic Complications
Completed NCT04119999 - A Cardiosleep Research Program on Obstructive Sleep Apnea, Blood Pressure Control and Maladaptive Myocardial Remodeling N/A
Recruiting NCT04505618 - Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease N/A
Recruiting NCT04863508 - Wearable Blood Pressure Devices to Identify Masked Uncontrolled Hypertension.
Completed NCT05185297 - Recreational Futsal for Controlled Hypertension N/A
Completed NCT03855605 - Diagnosis of Hypertension by Home Blood Pressure Monitoring
Completed NCT03901183 - Plant-based Nutrition for Patients With Cardiovascular Risk Factors N/A
Recruiting NCT03206814 - Improving Hypertension Control in CHina and ARGEntina With a Mobile APP-based Telecare System N/A
Recruiting NCT06343246 - Functional Inspiratory Muscle Training in Patients Diagnosed With Hypertension N/A
Completed NCT06359873 - Left Atrial Enlargement: A Crucial Indicator for Identifying Atrial Fibrillation in Patients With Hypertension
Recruiting NCT04565548 - Hypertension Treatment Adherence Improving Trial N/A
Recruiting NCT06205628 - Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension Phase 1
Recruiting NCT06052748 - A Study to Evaluate the Efficacy and Safety of AD-223 Phase 3
Recruiting NCT04613193 - Blood Pressure Reduction in Patients With Asymptomatic Aortic VALVE Stenosis N/A
Completed NCT03841383 - Association Between Coronary Flow Reserve and BH4 Levels in High CV Risk